By Hugo Geerts, PhD, Piet van der Graaf, PharmD, PhD
Over the past 20 years, less than a handful of completed Phase III Alzheimer disease (AD) clinical trials have been successful. Despite large investments of capital and research, more than 200 investigational programs have failed or …
